Filing Flows › Bionano Genomics (BNGO) › Q1 2026 › vs Q1 2025
Bionano Genomics (BNGO) Q1 2026 vs Q1 2025 (year over year)
Bionano Genomics's revenue rose $230K (+4%) from $6.5M in Q1 2025 to $6.7M in Q1 2026. The biggest changes: Product and Service Other +$140K (+31%); Product +$90K (+1%).
Bionano Genomics, Q1 2026: revenue $6.7M (+4% year over year), operating margin -118.1%, net loss $8.3M, operating cash flow −$5.7M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Consumable Revenue | $3.9M | $3.2M | $653K | +20% |
| Software Revenue | $1.2M | $2.1M | −$836K | -40% |
| Instrument Revenue | $962K | $689K | $273K | +40% |
| Product | $6.1M | $6.0M | $90K | +1% |
| Product and Service Other | $593K | $453K | $140K | +31% |
| Revenue | $6.7M | $6.5M | $230K | +4% |
| Net loss | $8.3M | $3.1M | $5.2M | +168% |
| Costs & expenses | $15.0M | $14.9M | $61K | +0.4% |
| Operating costs | $14.6M | $14.9M | −$338K | -2% |
| Interest & other, net | $396K | −$5.4M | $5.8M | — |
| Income tax | $10K | $7K | $3K | +43% |
| Cost of revenue | $3.4M | $3.5M | −$84K | -2% |
| Research & development | $3.1M | $2.4M | $769K | +32% |
| SG&A | $8.0M | $9.0M | −$1.0M | -11% |
| Operating cash sources | $8.7M | $6.8M | $1.9M | +28% |
| Depreciation & amortization | $2.3M | $2.4M | −$124K | -5% |
| Share-based compensation | $670K | $1.6M | −$917K | -58% |
| Cash used in operations | $5.7M | $2.8M | $3.0M | +107% |
| Net loss absorbed | $8.3M | $3.1M | $5.2M | +168% |
| Working capital & other | $393K | $3.7M | −$3.3M | -89% |
Questions
How much did Bionano Genomics's revenue grow year over year in Q1 2026?
Bionano Genomics's revenue rose $230K (+4%) from $6.5M in Q1 2025 to $6.7M in Q1 2026.
What drove Bionano Genomics's revenue change in Q1 2026?
Product and Service Other +$140K (+31%); Product +$90K (+1%).